| A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer (NCT05169684) | Bristol-Myers Squibb | 2022-02-14 |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer (NCT05156450) | West China Hospital | 2022-01-01 |
| Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy (NCT05902247) | Erasmus Medical Center | 2021-12-29 |
| 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) (NCT04868604) | Clarity Pharmaceuticals Ltd | 2021-08-11 |
| Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer (NCT04597411) | Endocyte | 2021-04-01 |
| Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer (NCT04717154) | Radboud University Medical Center | 2021-01-19 |
| Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (NCT04381832) | Arcus Biosciences, Inc. | 2020-07-07 |
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) (NCT04249947) | Poseida Therapeutics, Inc. | 2020-02-28 |
| Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions. (NCT04962919) | Latin American Cooperative Oncology Group | 2020-01-14 |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas (NCT04104776) | Novartis Pharmaceuticals | 2019-09-18 |
| Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects (NCT03927391) | Radboud University Medical Center | 2019-05-30 |
| Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer (NCT03822845) | Michael Graham PhD, MD | 2019-03-01 |
| A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223 (NCT03563014) | Bayer | 2018-07-31 |
| A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT03431350) | Janssen Research & Development, LLC | 2018-03-02 |
| 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer (NCT03389451) | Michael Graham PhD, MD | 2018-02-16 |
| 68Ga PSMA in Preprostatectomy Patients (NCT03388346) | Michael Graham PhD, MD | 2018-02-16 |
| Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients (NCT03173859) | University of Athens | 2018-01-01 |
| Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study (NCT03325127) | Bayer | 2017-10-30 |
| Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer ) (NCT02899104) | Bayer | 2017-06-15 |
| A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer (NCT03017417) | Sheffield Teaching Hospitals NHS Foundation Trust | 2017-02-08 |
| A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (NCT03016312) | Hoffmann-La Roche | 2017-01-10 |
| A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer (NCT02906605) | Janssen Research & Development, LLC | 2016-10-01 |
| A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer (NCT02592317) | Aragon Pharmaceuticals, Inc. | 2016-02-12 |
| Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer (NCT02625857) | Janssen Research & Development, LLC | 2015-12-10 |
| Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany (NCT02450812) | Bayer | 2015-05-28 |
| BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) (NCT02204072) | Boehringer Ingelheim | 2014-11-11 |
| Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer (NCT02057666) | Ipsen | 2014-01-01 |
| 68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly) (NCT04854369) | Tulane University | |